Epstein Secrets

From: "Jeffrey E." <[email protected]> To: Richard Kahn Subjec

From: "Jeffrey E." <[email protected]> To: Richard Kahn Su

. Links to Notes • Link to TEVA Note • Link to MYL Note • Link to MNTA Note Quick Background on Copaxone 3TW Litigation (from Sumant's note) Copaxone 3TW has new product exclusivity through 1/28/17 and is protected by five patents: '250, '413, '302, '776 and '874, which expire on 8/19/30. Today's IPR

<[email protected]> To: Richard Kahn Subject: Re: Add to TEVA and AGN Date: Thu, 25 Aug 2016 16:36:10 +0000 Dumb On Thursday, 25 August 2016, jeffrey E. <[email protected]> wrote: no On Thu, Aug 25, 2016 at 11:34 AM, Richard Kahn < > wrote: amanda is recommending we add to the two convertible pr

From: "Jeffrey E." <[email protected]> To: Richard Kahn Sub

. Links to Notes • Link to TEVA Note • Link to MYL Note • Link to MNTA Note Quick Background on Copaxone 3TW Litigation (from Sumant's note) Copaxone 3TW has new product exclusivity through 1/28/17 and is protected by five patents: '250, '413, '302, '776 and '874, which expire on 8/19/30. Today's IPR

From: Richard Kahn • To: "Jeffrey E." <[email protected]> Subject: Re: Add to

h Floor New York, NY 10022 tel faxcell On Aug 25, 2016, at 12:36 PM, jeffrey E. [email protected]> wrote: Dumb On Thursday, 25 August 2016, jeffrey E. <[email protected]> wrote: no On Thu, Aug 25, 2016 at 11:34 AM, Richard Kahn • > wrote: amanda is recommending we add to the two convertible pre

s EFTA00665657 • Link to TEVA Note • Link to MYL Note • Link to MNTA Note Quick Background on Copaxone 3TW Litigation (front Sumant's note) Copaxone 3TW has new product exclusivity through 1/28/17 and is protected by five patents: '250, '413, '302, '776 and '874, which expire on 8/19/30. Today's IPR

From: Richard Kahn c:I > To: "jeffrey EI Subject: Fwd: Allergen and Teva Date: Thu, 28 Jul 2016 17:47:26 +0000 Wadi merits: agn.pdf; teva.pdf; Cvt_Primer_2013_NEWEST.FDF !ohne-Images: ima

uct diversity are increasingly Important. • Our updated model is conservative vs. TEVA's issued 2017-19 outlook as we assume generic competition to Copaxone 3TW in '17. Company Description Teva, an Israeli/US generics company, is one of the largest companies in the global generic pharma industry and is beco